Riken Vitamin Co., Ltd. (TYO:4526)
Japan · Delayed Price · Currency is JPY 3,095.00
+35.00 (1.14%)
Feb 16, 2026, 3:30 PM JST
Riken Vitamin Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| 95,233 | 95,582 | 91,484 | 88,750 | 79,231 | 77,722 | |
Revenue Growth (YoY) | -0.05% | 4.48% | 3.08% | 12.01% | 1.94% | -6.33% |
Cost of Revenue | 65,453 | 64,312 | 61,598 | 61,506 | 53,666 | 55,711 |
Gross Profit | 29,780 | 31,270 | 29,886 | 27,244 | 25,565 | 22,011 |
Selling, General & Admin | 22,884 | 18,612 | 16,941 | 16,638 | 16,007 | 17,268 |
Research & Development | - | 3,642 | 3,315 | 3,220 | 2,992 | 3,094 |
Operating Expenses | 22,884 | 22,545 | 20,514 | 20,117 | 19,723 | 20,643 |
Operating Income | 6,896 | 8,725 | 9,372 | 7,127 | 5,842 | 1,368 |
Interest Expense | -117 | -123 | -112 | -132 | -178 | -665 |
Interest & Investment Income | 836 | 874 | 671 | 536 | 448 | 416 |
Currency Exchange Gain (Loss) | -226 | -230 | 267 | 42 | 82 | 513 |
Other Non Operating Income (Expenses) | 187 | 170 | 96 | 150 | 102 | 252 |
EBT Excluding Unusual Items | 7,576 | 9,416 | 10,294 | 7,723 | 6,296 | 1,884 |
Gain (Loss) on Sale of Investments | 5,417 | 4,055 | 2,090 | 184 | 14,127 | 303 |
Gain (Loss) on Sale of Assets | 159 | 295 | 3 | - | - | -4 |
Asset Writedown | -198 | -260 | -558 | -57 | -174 | -359 |
Other Unusual Items | 148 | -801 | 78 | 7 | 64 | -1,831 |
Pretax Income | 13,101 | 12,705 | 11,907 | 7,857 | 20,313 | -7 |
Income Tax Expense | 3,595 | 3,314 | 3,149 | 1,440 | -1,285 | 1,603 |
Earnings From Continuing Operations | 9,506 | 9,391 | 8,758 | 6,417 | 21,598 | -1,610 |
Minority Interest in Earnings | -3 | -3 | -3 | -3 | -16 | -8 |
Net Income | 9,503 | 9,388 | 8,755 | 6,414 | 21,582 | -1,618 |
Net Income to Common | 9,503 | 9,388 | 8,755 | 6,414 | 21,582 | -1,618 |
Net Income Growth | 11.68% | 7.23% | 36.50% | -70.28% | - | - |
Shares Outstanding (Basic) | 30 | 30 | 33 | 33 | 33 | 33 |
Shares Outstanding (Diluted) | 30 | 30 | 33 | 33 | 33 | 33 |
Shares Change (YoY) | -3.36% | -7.17% | -0.58% | 0.02% | 0.02% | 0.02% |
EPS (Basic) | 319.59 | 310.06 | 268.42 | 195.51 | 657.99 | -49.34 |
EPS (Diluted) | 319.59 | 310.06 | 268.42 | 195.51 | 657.99 | -49.34 |
EPS Growth | 15.57% | 15.51% | 37.29% | -70.29% | - | - |
Free Cash Flow | - | 3,214 | 7,915 | 5,723 | 3,573 | 3,928 |
Free Cash Flow Per Share | - | 106.15 | 242.66 | 174.45 | 108.93 | 119.78 |
Dividend Per Share | 108.500 | 94.000 | 81.000 | 59.000 | 46.000 | 42.000 |
Dividend Growth | 19.23% | 16.05% | 37.29% | 28.26% | 9.52% | - |
Gross Margin | 31.27% | 32.71% | 32.67% | 30.70% | 32.27% | 28.32% |
Operating Margin | 7.24% | 9.13% | 10.24% | 8.03% | 7.37% | 1.76% |
Profit Margin | 9.98% | 9.82% | 9.57% | 7.23% | 27.24% | -2.08% |
Free Cash Flow Margin | - | 3.36% | 8.65% | 6.45% | 4.51% | 5.05% |
EBITDA | 10,006 | 11,929 | 12,702 | 10,845 | 9,578 | 5,323 |
EBITDA Margin | 10.51% | 12.48% | 13.88% | 12.22% | 12.09% | 6.85% |
D&A For EBITDA | 3,110 | 3,204 | 3,330 | 3,718 | 3,736 | 3,955 |
EBIT | 6,896 | 8,725 | 9,372 | 7,127 | 5,842 | 1,368 |
EBIT Margin | 7.24% | 9.13% | 10.24% | 8.03% | 7.37% | 1.76% |
Effective Tax Rate | 27.44% | 26.08% | 26.45% | 18.33% | - | - |
Advertising Expenses | - | 1,208 | 964 | 1,204 | 1,460 | 2,762 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.